Skip to main content
SpringerLink
Log in

Effect of Gestational Exposure to Novel Antipsychotics on Body Weight Gain in Rats

  • Research Article
  • Published:
National Academy Science Letters Aims and scope Submit manuscript

Abstract

Clinical literature demonstrates that nearly all atypical antipsychotic drugs (AAPDs) are associated with weight gain. The magnitude of weight gain, however, varies between doses of drugs and exposure period as well as in different age groups. Data on AAPDs like quetiapine (QUE), risperidone and weight gain have been found variable in clinical and preclinical trials. The metabolic safety of these drugs in pregnant women has not been thoroughly investigated so far. Therefore, present study is designed to investigate the effect of gestational exposure to equivalent therapeutic doses of AAPDs, QUE and RISP on weight gain in female pregnant rats. The results indicate that there was mild reduction in body weight gain and food consumption in RISP exposed rats. Similarly, mild weight loss was also observed in QUE exposed dams inspite of significant drug induced anorexia/hypophagia. These drugs were found either neutral in weight gain or may induce mild weight loss in female adult rats. This study also demonstrates that multifunctional mechanisms might be involved for alteration in feeding pattern and body weight gain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Corripio I, Ferreira A, Portella MJ, Perez V, Escarti MJ, Camacho MV, Sauras RB, Alonso A, Grasa EM, Carrio I, Catafau AM, Álvarez E (2012) The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: Iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Res Neuroimag 201:73–77

    Article  Google Scholar 

  2. Panariello F, Polsinelli G, Borlido C, Monda M, De Luca V (2012) The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors. J Obes. Volume 2012, Article ID 572848, 7 pages

  3. De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, Souery D, Claes S (2012) Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 26(5):603–617

    Article  Google Scholar 

  4. Ferno J, Varela L, Skrede S, Vazquez MJ, Nogueiras R, Dieguez C, Vidal-Puig A, Steen VM, Lopez M (2011) Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 6:e20571

    Article  Google Scholar 

  5. Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, Lunder N, Dieguez C, Vidal-Puig A, Berge RK, Lopez M, Steen VM, Ferno J (2012) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology 219:783–794

    Article  Google Scholar 

  6. Goudie A, Cooper G, Halford J (2005) Antipsychotic-induced weight gain. Diabetes Obes Metab 7(5):478–487

    Article  Google Scholar 

  7. Ucok A, Gaebel W (2008) Side effects of atypical antipsychotics: a brief overview. World Psychiatry 7:58–62

    Google Scholar 

  8. Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(7):22–31

    Google Scholar 

  9. Statement Consensus (2004) Consensus development conference on antipsychotic drugs and obesity. Obes Res 12:362–368

    Article  Google Scholar 

  10. Gianfrancesco F, White R, Wang RH, Nasrallah HA (2003) Antipsychotic induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23:328–335

    Article  Google Scholar 

  11. Ozguven HD, Baskak B, Oner O, Atbasoglu C (2011) Metabolic effects of olanzapine and quetiapine: a six-week randomized, single blind, controlled study. Open Neuropsychopharmacol J 4:10–17

    Article  Google Scholar 

  12. Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR (2008) Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51:2309–2317

    Article  Google Scholar 

  13. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes Relat Metab Disord 29:607–614

    Article  Google Scholar 

  14. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Gilbert ME, MacPhail R, Baldwin J, Moser VC, Chernoff N (2010) Moderate developmental undernutrition: impact on growth and cognitive function in youth and old age. Neurotoxicol Teratol 32(3):362–372

    Article  Google Scholar 

  15. Koro CE, Fedder DO, L’Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:1–5

    Article  Google Scholar 

  16. Ota M, Mori K, Nakashima A, Kaneko YS, Fujiwara K, Itoh M, Nagasaka A, Ota A (2002) Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin Exp Pharmacol Physiol 29:980–989

    Article  Google Scholar 

  17. Fell MJ, Neill JC, Rao C, Marshall KM (2005) Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology 182:499–507

    Article  Google Scholar 

  18. Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NMKNY, Beaulieu S, Joober R, Richard D (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuro-Psychopharmacol Biol Psychiatry 28:1305–1311

    Article  Google Scholar 

  19. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41

    Article  Google Scholar 

  20. Wang PW, Hill SJ, Childers ME, Chandler RA, Rasgon NL, Ketter TA (2011) Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. J Psychiatr Res 45:1128–1132

    Article  Google Scholar 

  21. Stigler KA, Potenza MN, Posey DJ, McDougle CJ (2004) Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 6:33

    Article  Google Scholar 

  22. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychoticyouth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29(1):133–145

    Article  Google Scholar 

  23. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(1):1–93

    Article  Google Scholar 

  24. Rosengarten H, Quartermain D (2002) Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats. Pharmacol Biochem Behav 72:575–579

    Article  Google Scholar 

  25. Haupt DW (2006) Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16(3):S149–S155

    Article  Google Scholar 

  26. Levine JA, Eberhardt NL, Jensen MD (1999) Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 283:212–214

    Article  Google Scholar 

  27. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic in patients treated with olanzapine. Am J Psychiatry 159:1055–1057

    Article  Google Scholar 

  28. Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejìas MA, Hernàndez L (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834

    Google Scholar 

  29. Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. JPET 302:1129–1134

    Article  Google Scholar 

  30. Kotz CM (2006) Integration of feeding and spontaneous physical activity: role for orexin. Physiol Behav 88:294–301

    Article  Google Scholar 

  31. Cope MB, Li X, Jumbo-Lucioni P, DiCostanzo CA, Jamison WG, Kesterson RA, Allison DB, Nagy TR (2009) Risperidone alters food intake, core body temperature, and locomotor activity in mice. Physiol Behav 96:457–463

    Article  Google Scholar 

  32. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456–3459

    Article  Google Scholar 

  33. Pouzet B, Mow T, Kreilgaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133–140

    Article  Google Scholar 

  34. Stahl S (2003) Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Prim Care Companion J Clin Psychiatr 5:9–13

    Google Scholar 

  35. Goodnick PJ, Rodriguez L, Santana O (2002) Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3:1381–1391

    Article  Google Scholar 

  36. Molitch ME (2005) Medication-induced hyperprolactinemia. Mayo Clin Proc 80:1050–1057

    Article  Google Scholar 

  37. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22:195–214

    Article  Google Scholar 

Download references

Acknowledgments

Authors are thankful to Head, Department of Zoology, University of Allahabad, for providing laboratory facilities and University Grant Commission, New Delhi, India for financial assistance.

Conflict of interest

There is no conflict of interest between authors and funding agency.

Author information

Authors and Affiliations

  1. Neurobiology Laboratory, Department of Zoology, University of Allahabad, Allahabad, India

    K. P. Singh, Nidhi Tripathi & Manoj Kumar Singh

Authors
  1. K. P. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nidhi Tripathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manoj Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. P. Singh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, K.P., Tripathi, N. & Singh, M.K. Effect of Gestational Exposure to Novel Antipsychotics on Body Weight Gain in Rats. Natl. Acad. Sci. Lett. 37, 227–232 (2014). https://doi.org/10.1007/s40009-014-0225-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40009-014-0225-8

Keywords

Search

Navigation